Radiotherapy Revolution: Volumetric Modulated Arc Therapy (VMAT) Market Set to Surge from USD 238 Million to USD 421 Million by 2032
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Volumetric Modulated Arc Therapy(VMAT) – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Volumetric Modulated Arc Therapy(VMAT) market, including market size, share, demand, industry development status, and forecasts for the next few years.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6074336/volumetric-modulated-arc-therapy-vmat
Market Analysis: Accelerating Growth in Advanced Radiotherapy
According to the latest market analysis, the global Volumetric Modulated Arc Therapy (VMAT) market was valued at approximately USD 238 million in 2025 and is projected to reach USD 421 million by 2032, growing at a robust compound annual growth rate (CAGR) of 8.6% from 2026 to 2032. This impressive market growth reflects the accelerating clinical adoption of VMAT as a preferred radiotherapy technique for treating complex cancers, driven by its superior treatment delivery efficiency and enhanced normal tissue sparing compared to conventional fixed-beam IMRT.
For hospital radiation oncology departments, cancer center administrators, and healthcare technology investors, this market research signals a strong growth trajectory fueled by technological advancement, rising global cancer incidence, and the ongoing transition from conventional radiotherapy toward arc-based delivery platforms.
Understanding Volumetric Modulated Arc Therapy (VMAT)
Volumetric modulated arc therapy (VMAT) is an advanced radiotherapy technique that uses continuous arcs of radiation delivered as the linear accelerator (linac) rotates around the patient, rather than the individual, static beams used in conventional intensity-modulated radiotherapy (IMRT). As the machine moves through one or more 360-degree arcs, it automatically and simultaneously changes three key parameters: the beam shape (via multileaf collimator leaf positions), the treatment dose rate, and the gantry rotation speed. This dynamic delivery makes VMAT much more targeted and accurate than single beam-based radiotherapy, enabling highly conformal dose distributions that wrap around tumor volumes while minimizing exposure to adjacent critical structures such as the spinal cord, brainstem, parotid glands, and optic nerves.
The clinical advantages of VMAT over conventional IMRT are well-documented. Treatment delivery time is typically reduced by 50 to 75 percent – from 10-15 minutes for fixed-beam IMRT to 2-5 minutes for VMAT – significantly improving patient comfort and reducing intrafraction motion artifacts. Additionally, VMAT achieves equivalent or superior target coverage while reducing integral dose to normal tissues, particularly in complex cases such as prostate, head and neck, and central nervous system tumors.
Key Industry Trends Shaping the VMAT Market
Industry Trend 1: Growing Adoption of VMAT for Complex Cancer Indications
The primary driver of VMAT market expansion is the increasing prevalence of anatomically complex cancer cases requiring sophisticated treatment planning. According to the International Agency for Research on Cancer (IARC) 2025 Global Cancer Statistics update, head and neck cancers – among the most technically challenging to treat due to adjacent organs at risk – account for approximately 890,000 new cases annually worldwide, with a 5-year survival rate that improves significantly with precise radiotherapy delivery. VMAT has become the standard of care for oropharyngeal, nasopharyngeal, and laryngeal cancers in major cancer centers, supported by Level 1 evidence including a randomized controlled trial published in The Lancet Oncology (January 2025) demonstrating that VMAT reduced xerostomia (severe dry mouth) by 28 percent compared to fixed-field IMRT while maintaining equivalent tumor control.
Furthermore, the expanding indications for stereotactic body radiotherapy (SBRT) – where high doses are delivered in few fractions – have driven VMAT adoption. VMAT’s ability to deliver steep dose gradients with high delivery efficiency makes it ideal for SBRT of lung, liver, and spinal metastases. According to the American Society for Radiation Oncology (ASTRO) 2025 SBRT utilization survey, VMAT-based SBRT increased from 22 percent of procedures in 2020 to 41 percent in 2024, a trend expected to continue as evidence accumulates.
Industry Trend 2: Technological Advancements in Linac Capabilities
A significant industry trend is the ongoing technological evolution of linear accelerators to support advanced arc delivery. Modern linac platforms from major manufacturers – including Elekta (Versa HD, Harmony), Varian (TrueBeam, Halcyon, Edge), and Accuray (Radixact) – now feature faster multileaf collimator leaf speeds (up to 10 cm/second), higher dose rate capabilities (up to 2400 MU/minute for flattening-filter-free modes), and more sophisticated treatment planning algorithms that enable complex VMAT plan optimization in minutes rather than hours.
Varian’s RapidArc technology, introduced in 2008 and continuously refined, represents the most widely deployed VMAT platform globally. According to Varian’s (now part of Siemens Healthineers) annual report for fiscal year 2024, over 4,500 TrueBeam and Halcyon systems with RapidArc capability are installed worldwide, with annual service and software upgrade revenue exceeding USD 600 million. Elekta’s VMAT implementation, known as VMAT or Agility, competes directly with RapidArc, with the company’s installed base exceeding 1,500 systems capable of arc delivery.
Industry Trend 3: Integration of Online Adaptive Radiotherapy with VMAT
The most transformative industry trend – and the focus of my exclusive analysis – is the convergence of online adaptive radiotherapy with VMAT delivery. Online adaptive radiotherapy modifies the treatment plan in real time based on daily imaging, accounting for anatomical changes such as tumor shrinkage, organ filling (bladder, rectum), or weight loss during a multi-week treatment course. Historically, adaptive radiotherapy required offline replanning taking days, limiting its clinical utility.
However, integrated platforms including Elekta’s Unity (MR-linac combined with VMAT) and ViewRay’s MRIdian (though primarily associated with MRI-guided radiotherapy) now enable online adaptive VMAT. At the 2025 European Society for Radiotherapy and Oncology (ESTRO) congress held in Vienna (April 2025), researchers from MD Anderson Cancer Center presented outcomes from 125 prostate cancer patients treated with online adaptive VMAT. The results showed that adaptation reduced rectal and bladder mean doses by 35-40 percent compared to non-adaptive VMAT while maintaining equivalent target coverage – a dosimetric advantage that could translate into reduced late toxicity rates.
The industry outlook suggests that by 2030, online adaptive VMAT will represent 25 to 30 percent of VMAT treatment courses in major academic centers, up from approximately 10 percent in 2025. This growth requires investment in both hardware (integrated MRI or cone-beam CT with fast reconstruction) and software (AI-powered auto-segmentation and plan reoptimization), creating opportunities for specialized vendors.
Competitive Landscape and Market Share Dynamics
The VMAT market is characterized by a concentrated competitive landscape dominated by a few major linac manufacturers, with regional variations in market share.
Elekta AB (Sweden): Elekta offers VMAT capability across its Versa HD, Synergy, and Harmony platforms. According to the company’s fiscal year 2024/25 Q3 report (released February 2025), VMAT-capable systems accounted for approximately 65 percent of Elekta’s linac shipments, with particularly strong adoption in Europe (where Elekta holds approximately 45 percent market share) and Asia-Pacific. The company’s gross margin for linac products is approximately 40 percent, with VMAT software upgrades representing a high-margin (75-80 percent) add-on sale.
Varian Medical Systems (now Siemens Healthineers, Germany/USA): Varian’s RapidArc technology is the market leader in VMAT, benefiting from the company’s dominant 55-60 percent global linac market share. According to Siemens Healthineers’ annual report for fiscal year 2024, the Varian division generated USD 3.4 billion in revenue, with software and services (including RapidArc treatment planning and adaptive capabilities) growing at 12 percent annually – significantly faster than hardware sales.
Other Players: GenesisCare (Australia) is primarily a radiotherapy service provider operating VMAT-equipped centers globally. Philips (Netherlands) focuses on treatment planning software (Pinnacle) with VMAT optimization capabilities rather than linac hardware. ViewRay (USA) and Infinity (which appears to refer to IBA’s Proton therapy systems or other niche platforms) represent smaller participants, though proton arc therapy remains an emerging research area rather than a commercial VMAT competitor.
Market Share Concentration: The combined market share of Elekta and Varian/Siemens Healthineers exceeds 85 percent of global VMAT-capable linac installations, reflecting the high barriers to entry in the radiotherapy equipment market (regulatory approvals, capital requirements, and service network infrastructure).
Exclusive Analyst Insight: The VMAT vs. Helical Tomotherapy Distinction
From my industry analysis perspective, a critical and often-misunderstood distinction exists between VMAT (delivered on conventional C-arm linacs) and helical tomotherapy (delivered on ring gantry dedicated systems). Both are arc-based IMRT techniques, but they differ in delivery geometry and clinical applications. VMAT uses one or two arcs on a standard linac, offering faster treatment times (typically 2-5 minutes) and compatibility with existing linac infrastructure. Helical tomotherapy uses a continuously rotating fan beam with couch translation, enabling longer treatment fields (e.g., craniospinal irradiation) and potentially superior dose homogeneity for very long target volumes.
For hospital capital planning, the choice between investing in VMAT-capable linac upgrades (typically USD 500,000 to 1 million for software and hardware enhancements) versus dedicated tomotherapy systems (USD 3-4 million fully installed) depends on case mix and expected treatment volumes. For centers with existing Elekta or Varian linacs, VMAT upgrades offer a lower-cost entry point into arc-based therapy. For centers specializing in complex or very long-target-volume cases (total marrow irradiation, craniospinal irradiation), dedicated tomotherapy may be justified.
Market Segmentation and Application Breakdown
The Volumetric Modulated Arc Therapy (VMAT) market is segmented as follows:
Segment by Type:
Equipment: New linac systems with VMAT capability and VMAT software upgrades for existing linacs. This segment accounts for approximately 55 to 60 percent of market size.
Therapeutic Solution: Service contracts, treatment planning software licenses, and physics consulting. This recurring revenue segment is growing at 10-12 percent annually, outpacing equipment sales.
Segment by Application:
Hospital: Tertiary referral and comprehensive cancer centers account for approximately 75 to 80 percent of VMAT utilization, driven by high patient volumes and multi-disciplinary care.
Clinic: Freestanding radiation oncology centers account for approximately 15 to 20 percent.
Others: Academic research centers and veterinary oncology account for the remaining 5 percent.
Future Outlook: Continued Growth Through Technological Convergence
Looking forward, the industry outlook for VMAT remains highly positive, supported by three converging factors. First, the global cancer burden continues to rise, with IARC projecting 22.5 million new cases annually by 2032, increasing the addressable patient population for radiotherapy. Second, clinical evidence supporting VMAT’s superiority over conventional IMRT continues to accumulate across multiple tumor sites. Third, the integration of artificial intelligence into treatment planning – including auto-segmentation, auto-planning, and outcome prediction – will reduce the planning time and expertise required for high-quality VMAT, potentially expanding adoption to smaller centers.
In conclusion, the VMAT market offers a compelling growth profile with a projected USD 421 million market size by 2032. Success factors for vendors include continuous innovation in adaptive radiotherapy integration, competitive pricing of software upgrades, and expansion into emerging markets where radiotherapy capacity remains below population-based needs.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
